Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

HeiLongJiang ZBD Pharmaceutical Co Ltd

603567:SHH

HeiLongJiang ZBD Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.40
  • Today's Change0.04 / 0.35%
  • Shares traded8.04m
  • 1 Year change-12.04%
  • Beta0.7937
Data delayed at least 15 minutes, as of Nov 01 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.

  • Revenue in CNY (TTM)2.58bn
  • Net income in CNY114.60m
  • Incorporated1996
  • Employees2.55k
  • Location
    HeiLongJiang ZBD Pharmaceutical Co LtdNo. 8Yantai First Road, Pingfang DistrictHAERBIN 150060ChinaCHN
  • Phone+86 45 186811969
  • Fax+86 45 187105767
  • Websitehttp://www.zbdzy.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhejiang Hisun Pharmaceutical Co., Ltd.9.55bn-34.96m10.06bn8.06k--1.22--1.05-0.0412-0.04128.206.830.5553.234.281,184,162.00-0.34671.95-0.56633.7739.0840.58-0.62483.430.6491--0.369626.07-13.820.3618-119.05---31.58--
Youcare Pharmaceutical Group Co Ltd3.95bn96.27m10.12bn3.18k105.162.80--2.560.21380.21388.768.040.67132.214.431,241,400.001.657.112.4811.6557.1564.142.458.071.404,818.810.197760.95-7.611.05-44.84-7.1623.40--
Changchun BCHT Biotechnology Co1.61bn414.29m10.53bn1.24k25.422.51--6.551.001.003.8810.150.31811.001.061,295,333.008.209.9510.2312.8187.5586.6325.7724.031.85--0.014710.5570.3012.36175.9831.3721.04--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.58bn421.47m10.64bn1.55k25.704.07--6.751.881.887.1411.910.42861.193.671,020,281.0011.585.8616.997.5967.1255.4127.0117.200.91224.020.347727.5958.6932.2426.2029.9927.32--
Heilongjiang ZBD Pharmaceutical Co Ltd2.58bn114.60m10.74bn2.55k95.501.38--4.160.11940.11942.748.240.21181.480.76451,014,704.000.88223.481.174.7834.5238.934.1710.082.23--0.288827.18-25.502.45155.000.4417-25.684.05
Chongqing Genrix Biophrmctcl Co Ltd13.56m-779.42m10.87bn547.00--4.62--801.76-2.13-2.130.0376.420.00390.10091.3724,790.27-22.22---23.06--55.87---5,747.82--18.62--0.2454--154.92---39.03------
Guobang Pharma Ltd5.71bn702.28m10.87bn4.23k15.441.39--1.901.261.2610.2614.030.55993.297.841,350,536.006.8710.368.8814.2423.8727.4912.2715.011.70--0.199218.24-6.4910.28-33.4923.7735.60--
Mayinglong Pharmaceutical Group Co Ltd3.48bn482.37m10.92bn2.88k22.642.73--3.141.121.128.089.280.68726.428.531,208,299.009.7410.8211.6413.4744.8441.1814.1714.084.40--0.093633.04-11.207.38-7.4620.2658.3321.67
Liaoning Chengda Biotechnology Co Ltd1.72bn332.10m11.19bn1.73k33.471.17--6.520.80320.80324.1622.930.17020.7631.43991,973.803.2910.633.4111.0180.5385.7419.3339.5617.44--0.001831.53-3.584.71-34.75-5.5639.78--
KPC Pharmaceuticals Inc7.55bn446.07m11.39bn5.05k25.412.06--1.510.59240.592410.037.310.78192.752.561,494,697.004.645.427.759.1340.8443.685.945.701.51--0.17235.75-6.991.6416.055.79-21.3314.87
Data as of Nov 01 2024. Currency figures normalised to HeiLongJiang ZBD Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.09%Per cent of shares held by top holders
HolderShares% Held
Shenwan Hongyuan Asset Management (Asia) Ltd.as of 30 Sep 20234.50m0.48%
China Merchants Fund Management Co., Ltd.as of 30 Jun 20244.48m0.48%
Da Cheng Fund Management Co., Ltd.as of 30 Jun 20242.17m0.23%
China Universal Asset Management Co., Ltd.as of 30 Jun 20241.75m0.19%
China Southern Asset Management Co., Ltd.as of 30 Jun 20241.74m0.19%
The Vanguard Group, Inc.as of 30 Sep 20241.42m0.15%
China Post & Capital Fund Management Co., Ltd.as of 30 Jun 20241.20m0.13%
China Asset Management Co., Ltd.as of 30 Jun 2024985.80k0.11%
GF Fund Management Co., Ltd.as of 30 Jun 2024888.10k0.09%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024590.80k0.06%
More ▼
Data from 31 Dec 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.